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Abstract 
An infertile C. elegans mutant fer-1 was identified as a suitable substitute for wild type in 
evaluating the pathogenesis of C. albicans using a survival assay. The response of fer-1 mutant 
worms infected with avirulent C. albicans mutants or treated with fluconazole is statistically 
indistinguishable from the wildtype counterpart. The lifespan of uninfected fer-1 worms is 
marginally yet reproducibly shorter than wildtype, but the lack of progeny in sterile mutants 
makes them an ideal choice for otherwise labor-intensive lifespan analyses.  
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Introduction 
The Candida albicans pathogen  
Candida albicans’ notoriety 
 Candida albicans is a commensal organism that colonizes humans’ mouths, 
gastrointestinal and uro-genital tracts and exists without harm to the host (Joualt, 2009). 
However, C. albicans colonization is a threatening condition in immunocompromised patients, 
such as those with HIV/AIDS. Other high risk populations include those under broad-spectrum 
antibiotic treatment and organ failure (Blumberg, 2001). When the innate immune system of an 
individual is compromised, his or her ability to fight off a fungal infection is drastically 
impaired, leading to a high mortality rate (Jarvis, 1995). This risk is particularly high upon 
infection of the bloodstream – candidemia – primarily seen in patients with intravenous catheters 
or other medical implants (Blumberg, 2001). 
Candida infections are the largest component of nosocomial infections, especially those 
of the urinary tract, or UTIs (Achkar, 2010). A case study of Candida infections reported in the 
ICU of a particular hospital (Leleu, 2002) disclosed overwhelming statistics. Analyzing 
candidiasis and candidemia cases at this hospital over a three year period recorded that 0.3% of 
ICU admissions developed confirmed Candida infections, 84% of which are caused by Candida 
albicans. This average can range significantly between hospitals and even reach as high as 
1.58% of admissions (Rangel-Frausto, 1999). This study also correlated candidiasis and 
candidemia with increased mortality, longer hospital stays, acute respiratory distress, shock, and 
workload on the hospital. Therefore, Candida infections are not only a threat to public health, but 
a stress to the infrastructure and management of the health care system, pressuring their time, 
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energy, and money. Thus, there is an urgency to learn more about how this specific fungus 
causes a disease and how the immune system reacts to the infection. 
How C. albicans infects 
Much research has been conducted to investigate the pathways involved in Candida 
albicans virulence. Various studies (Gow, 2002; Money, 2001; Hube, 2001) reveal that the 
morphological transition from yeast to hyphae (or pseudohyphae) are associated with infection 
because these morphologies are more invasive. Hyphae have pathogenic advantages that yeast 
form cells do not have in that they can extend the tips of the hyphae with a considerable amount 
of pressure, comparable to that of 8% agar (Money, 2001). The hyphae thus poke through and 
kill the macrophages that ingest the cells (Gow, 2002). Hyphae can also navigate the topography 
of nearby host cells with the hyphal tips, locating weak, vulnerable spots best for infection – a 
process called thigmotropism, or contact guidance (Hardham, 2001). In addition, hyphae tips 
secrete proteases and enzymes that degrade lipids in order to dissolve a path of infection ahead of 
the cell. Of high interest recently are the secreted aspartyl proteases (SAPs) known to enhance C. 
albicans virulence (Hube, 2001). 
These hyphal filamentation processes are controlled by various pathways, including the 
Czf1, Cph1, Cph2, RascAMP and MAPK pathways and Efg1 transcription factor. Inactivating 
Tup1 and CaNrg1 as well as activating a pH pathway at an ambient pH cause Candida to 
filament (Gow, 2002). Interestingly, Tup1, Nrg1, Efg1, Cph1 and Cph2 also regulate other 
virulence phenotypes such as adhesion and the secretion of proteases (Murad, 2001). Despite the 
advantages of the hyphal form, yeast form cells have been demonstrated to disseminate better 
than hyphae through the circulatory system. (Gow, 2002). The studies have only scratched the 
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surface of uncovering the pathogenicity of C. albicans and have mainly only applied candidate 
gene approaches to the research. 
 Shortage of Anti-fungal Drugs  
Currently, drugs available to treat fungal infections are minimal. Antibiotics are very 
common partially because bacteria are prokaryotic, and have different features such as 
peptidoglycan in their membranes that allow drugs to work without adversely affecting the 
human. As fungi are eukaryotic, they share many similarities with their hosts, whether it is an 
animal or a human. This largely limits the drugs available for patients as many will harm the 
patient while attacking the fungus. Nevertheless, several antifungal agents have been developed 
since in the past sixty years, as seen in Figure 1 below. 
 
Figure 1: Known antifungal agents used to treat systemic infections in the United States (Dismukes, 2000) 
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Figure 2: Mechanism of Amphotericin B on a fungus  
 As an example, the “gold standard” of antifungal drugs is Amphotericin B. It functions 
by binding with ergosterol and forming channels in the membrane which causes necessary ions 
such as potassium and sodium to leak out, eventually leading to cell death as shown in Figure 2. 
However, mammalian cells are composed of cholesterol, a very similar compound. Because they 
are so similar, Amphotericin B is toxic to the mammal as well as the fungus. Amphotericin B is 
often a last resort for doctors as it is limited by infusion-related toxicity (Thompson et. al., 2008). 
However, in the case of a bloodstream infection, Amphotericin B is often the first drug to be 
used (Anaissie, 1996).  
 Another family of antifungals that is more commonly used, is Echinocandins, i.e. 
caspofungin
TM
 (Merck Inc.), are commonly used as a first line of therapy. The side effects aren’t 
frequent, and it has a favorable drug interaction profile (Thompson et. al., 2008). The drug works 
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by inhibiting the synthesis of β(1,3)-D-glucan, an integral component in fungal cell walls. It 
inhibits further growth of fungi by eliminating this crucial structural protein. It is also fungicidal 
in that it removes the stability of the cell, causing it to eventually lyse from osmotic pressure. It 
is not present in mammalian cells, drastically reducing the issue of toxicity (Letscher-Bru, et al., 
2003). However, multiple strains of Candida have become resistant to the drug with prolonged 
exposure. Specifically with Caspofungin, many of the isolated mutations were linked to the 
glucan synthase complex which was reported to be a mutation hotspot. In C. glabrata, the most 
common mutation seen was F659V, and in C. krusei, R1361G (Thompson et. al., 2008). 
 Another common, first line antifungal drug family is the azole family. There are many 
different azoles, including fluconazole, itraconazole, and voriconazole. Fluconazole is one of the 
more well-known and prescribed antifungal medications. There have been numerous studies on 
fluconazole as well as Candida’s ability to resist the drug.  
 Azole drugs target the enzyme lanosterol demethylase in the ergosterol biosynthetic 
pathway (Figure 3). Instead of incorporating ergosterol into the membrane, toxic sterols are 
instead included which compromise the stability of the membrane.  Perea et al. found that 
fluconazole resistance did not infer resistance to itraconazole and other members of the –azole 
family. However, many patients had a decreased susceptibility to the other drugs in the family. It 
was seen that the most common mechanism for resistance was efflux pumps. Fluconazole 
resistant strains were not resistant to Amphotericin B as the mechanisms are not comparable and 
the drugs are not related. Therefore resistance to one would not cause resistance to the other 
(Perea et al. 2001). 
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Figure 3: Mechanism by which an azole works on a fungus 
  It was found that many of the genes that control efflux pumps were either upregulated or 
overexpressed in almost all of the patients studied. Specifically, CDR genes were overexpressed: 
MDR1 and ERG1 were upregulated in most of the patients (Perea et al. 2001). This increase in 
efflux pumps prevents azoles from reaching a high enough concentration to destabilize the 
membrane through the production of toxic sterols in the membrane. 
When the strains that were fluconazole resistant were isolated and analyzed, eleven 
different mutations were found. Nine of the mutations had previously been isolated. Because 
many of these mutations occur near each other with respect to base pair number, it indicates that 
there are mutational hot spots. In this case, it was found that many of the mutations occurred in 
regions that involved binding or the active site (Perea, et al. 2001).  
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There are many strains that are resistant to different antifungal drugs. The development of 
chemosensitizers, or other compounds that can surpass resistance is part of a new method for 
improving antifungal drugs. Youngsaye et al. (2011) found that piperazinyl quinolone functioned 
as a chemosensitizer, increasing the susceptibility of Candida to fluconazole. Even though many 
compounds were tested, piperazinyl quinolone was found to be the most effective 
chemosensitizer. This compound’s use as a chemosensitizer is not necessarily feasible as it is not 
easily soluble. Benefits of the compound are that alone, it is not inherently toxic or fungicidal. 
Also, it did not act through an established resistance pathway.  
  Oloki et al. (2009) screened a library of 3,228 compounds, and isolated nineteen of 
which have antifungal abilities. Seven of the isolated compounds are known antifungal drugs. 
The other twelve compounds fall into three different categories: the compound is not soluble in 
water, the compound kills the worms as well as the fungus, and the compound is not effective 
against the specific fungus used in the assay but is effective against most others. Most of the 
isolated compounds have antifungal activity, but have problems that would derail its clinical use. 
For example, concanamycin A had the highest antifungal activity of the compounds tested, but it 
is highly toxic. Some of the other compounds isolated appeared to have antifungal effects in vivo 
but not in vitro. 
In collaboration with the Kaufman lab, the Prusty Rao lab completed a screen for 
possible compounds that could be used as a component to an antifungal. Out of the 30,000 
compounds screened, one was isolated for further testing in mice after utilizing the C. elegans 
assay as a secondary screen.  
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C. elegans for an innate immune system model 
Model organisms for the host immune system 
 Various animals, including the fruit fly Drosophila melanogaster, the caterpillar Galleria 
mellonella and mice, are studied for their immune systems’ reactions to various pathogens. To 
infect the animal, it is injected with the pathogenic bacteria or fungus to detect changes and 
components that may be related to the innate immune system (Miyata, 2003). Specific responses 
in Drosophila to the fungus B. bassiana and the Gram-negative bacteria S. marcescens and E. 
carotovora have been studied, among other pathogens, revealing a Toll-like receptor pathway 
and JNK pathway similar to that of humans, and an induced antimicrobial peptide entitled 
drosomycin (Leclerc, 2004). The innate immune responses in Galleria to various fungi 
(Mylonakis, 2008) and the bacteria P. aeruginosa (Miyata, 2003) have been elucidated and a 
myriad of immunological investigations in mice have been conducted as well. 
An animal that has gained popularity for studying host innate immune responses is C. 
elegans. Although the nematode does not have an acquired immune system like humans, its 
innate immune system – the process by which fungal infections are predominantly fought – has 
many analogous features and processes. Moreover, the worm C. elegans is an ideal model for 
studying host immune system responses because of its short lifespan of about three weeks, the 
simplicity of infecting the worm by plainly feeding it the pathogen, and the ability of the 
hermaphrodite to self-fertilize, which together allow for relatively straightforward, high-
throughput genetic screens and survival assays (Kurz, 2000). 
In genetic analyses of C. elegans, mutagenesis is done on a first generation, and their 
progeny, F2, are observed for certain phenotypes. Since the worms self-fertilize, a mutation 
should be homozygous and thus visibly present in a quarter of the F2 progeny. Another 
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advantageous characteristic of C. elegans for use in genetic analyses is its arrested growth in the 
absence of food, known as the dauer stage. Worms slow their metabolism and remain arrested in 
growth, which may be used to synchronize them for use in a survival or an infection assay. 
Finally, C. elegans is an excellent model for genetic study because compared to screens with 
mice and other mammalian systems, the worms take a great deal less time, labor and money and 
because facets of the innate immune response, the main defense against fungal infections, is 
conserved between humans and C. elegans (Kurz, 2003). Throughout the course of a survival 
assay, there are various levels of C. albicans pathogenesis and of disease in the worms. Below is 
a depiction (Figure 4) of an infected C. elegans at its worst, when hyphae take over the organism 
and burst through it. 
 
Figure 4: C. elegans infected with C. albicans 
The C. albicans that the C. elegans ingested converted to the pathogenic  
hyphal form, poking through the cuticle of the worm and killing it. 
The C. elegans innate immune system 
C. elegans is an ideal organism for conducting genetic analyses and observing immune 
responses because its antimicrobial peptides, MAPK pathway and several other processes are 
comparable to those of the human innate immune system. The first level of the C. elegans 
immune system that is analogous to humans’ entails the secretion of antimicrobial peptides, or 
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AMPs from epithelial cells in the mouth and gastrointestinal tract. Additionally, the grinder 
made of chitin in the pharynx breaks down most pathogens that are ingested, since C. elegans 
feeds mainly on microorganisms (Kurz 2003). The AMP molecules are rich in glycine and 
tyrosine (Pujol, 2008), are small (about thirty to forty residues long) and their genes are often 
assembled as operons. One AMP, abf-2, was detected in excretory cells with a GFP tag and 
discovered to be somewhat effective against several fungal species: S. cerevisiae, P. anomala, D. 
hansenii, C. krusei (Kato, 2002). Antimicrobial peptides are fascinating to study because they 
evolve very quickly and frequently, as a result of the “battle” between host and pathogen – co-
evolution (Netea, 2008). 
After the initial level of defense at the epithelial cells, a series of cellular processes for 
microbes in general or specifically for fungal pathogens are activated in response to infection. 
Well known in cellular biology is the p38 mitogen-activated protein kinase pathway, or MAPK 
pathway, which partakes in immune system responses against pathogens. While sek-1 and nsy-1 
are proteins identified in the human MAPK pathway, esp-2 and esp-8 were identified as the 
homologous proteins in the C. elegans MAPK pathway (Kim, 2002). These proteins, sek-1 and 
nsy-1, activate pmk-1, which in turn stimulates pathogen-fighting cells like macrophages and 
interleukins (Kurz, 2003). The proteins of the MAPK pathway also promote apoptosis in cells 
already affected and damaged by the infection (Aballay, 2001). Downstream of these proteins in 
the MAPK pathway in C. elegans are nlp29 and 31, neuropeptide-like proteins that are activated 
by NIPI3, the protein analogous to Tribbles homolog 1 in humans based on their catalytic 
domains (Pujol, 2008). Furthermore, the extracellular-signal-regulated protein kinase (ERK), the 
JUN kinase (Kurz, 2003) and the TGFβ signaling pathways (Tan, 2001) contribute to the 
activation of immune responses. 
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Host responses specific to C. albicans 
The above pathways are general immune system responses to most pathogens, but there 
are some responses specific to fungi. On the surface of the cell are PAMPs (pathogen-associated 
molecular patterns) called glycophosphatidylinositol (GPI)-anchor-dependent cell wall proteins 
unique to fungi, making them identifiable to the immune system. These proteins are highly 
glycosylated with polysaccharides containing mannose, known as mannan. The two main types 
of mannan are O-linked mannan which is short and linear and N-linked mannan which is highly 
branched (Netea, 2008). In fact, N-linked mannan has been directly related to candidiasis and 
fungal load in mice organs. Mannose receptors (MR) on the surface of macrophages and 
monocytes recognize and bind the N-linked mannosyl residues and Toll-like receptor (TLR) 4 
recognizes O-linked mannosyl residues (See Figure 4 below). Recognition at these receptors, 
especially MR, stimulates cytokines like TNFα, IL-1β, IFN-γ and IL-6. Some cytokine 
stimulation is brought about with the help of MyD88, the myeloid differentiation primary 
response gene 88, which is an intracellular TLR adaptor molecule. Minimal cytokine stimulation 
(IL-2, -10 and -17) results from laminarin, a C. albicans ligand rich in β1,3-glucan (Netea, 
2006). The β-glucans are detected by the dectin-1 receptor, but can only be bound, along with 
chitin, when exposed because a new cell buds. β-glucans and chitin are at the core of the cell 
wall, and they hydrogen-bond to create a strong network of fibers (Netea, 2008). Stimulating 
these various cytokines in turn recruits neutrophils, macrophages and monocytes to ingest the 
Candida (Van’t Wout, 1988) and polymorphonuclear (PMN) leukocytes (Netea, 2008). 
Besides inducing cytokines and ingesting pathogenic cells, toxic oxygen and nitrogen 
radicals are a strong defense mechanism used by the host to fight infection (Djeu, 1990). In a 
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process known as respiratory burst, toxic and oxidative free radicals activate proteases that attack 
the invading microorganism (Aratani, 1999). 
 
Figure 5: Receptors, PAMPs and consequent pathways activated in response to Candida albicans infection (Netea, 2008) 
In addition to the pro-inflammatory responses described, Candida albicans also causes 
anti-inflammatory responses, because of its status as a commensal organism and because of its 
dimorphic nature. For instance, dectin 2 specifically recognizes hyphae, especially its mannose. 
Moreover, the receptor CR3 that recognizes β-glucans is immunosuppressive (Netea, 2008), as 
are the cytokines IL-4 and IL-10 (Tonnetti, 1995). There is a fine line – a balance – between 
controlling the commensal organism or low-grade infection, and a progression into disease 
(Romani, 2004). For this reason, there are various pathways with different magnitudes and 
kinetics to become specific to yeast or hyphae, commensal organism or pathogen (Netea, 2008). 
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The pathogenesis assay 
C. elegans was chosen for this research over mice, fruit flies and caterpillars for a 
multitude of reasons. The worms’ innate immune system is similar to that of humans, which is 
the part of the immune system that fights off fungal infections. It is also capable of simply 
ingesting the Candida off the agar plate where C. elegans lives, whereas caterpillars, mice, and 
fruit flies would have to be injected with the fungus. The upkeep for worms is simple, and it is 
possible to maintain stocks for experiments.  
The Dar assay (Jain et. al., 2009; Gravato-Nobre, 2005) is one of the few assays used to 
survey infections in C. elegans. It does not require the death of worms; infection is based upon 
the appearance of the deformed anal region (Dar) upon ingesting C. albicans present on an agar 
plate, mixed with the standard diet of attenuated E. coli OP50. While this is a fairly short assay 
of four to six days and an indication of whether or not a worm has been infected, Dar can be 
subjective and difficult to identify. 
In order to definitively distinguish particular immune responses or the lack thereof, the 
Dar assay must be followed by a more vigorous survival assay. In the survival assay, a 
population of worms is tracked from the start of infection until death. The current survival assay 
protocol requires transferring parents away from their progeny every other day – a time-intensive 
task. Worms must be counted every day as well. When counting, worms must be classified as 
alive, dead or censored if they die of unrelated causes such as dehydration. 
 The main objective for this project is to optimize the assay in order to not have to transfer 
the worms every other day and to make it more manageable. By switching to bigger plates and 
using sterile worms, transferring should only have to occur every couple of days. Ideally, worms 
should only have to be transferred every three to four days. By optimizing and validating this 
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assay, potential antifungal drugs can simply be added to the food spot and compared to a control 
plate to directly visualize their effects on the survival of C. elegans. 
 In order to streamline this process, we propose the use of the sterile mutant fer-1 in the 
survival assays as it is not able to reproduce at 25ᵒC.  A mutation in fer-1 prevents the 
spermatids’ membranous organelles from fusing with the plasma membrane and from forming 
short pseudopods, causing immobility (Achanzar, 1997). This stops sperm from penetrating into 
an egg which will prevent fertilization and the laying of eggs, the reason that the worms have to 
be transferred so frequently. Instead, the hermaphroditic worms lay unfertilized oocytes, which 
are noticeable because they are round, compared with the oval-shaped fertilized eggs (McCarter, 
1999). Along with switching to the sterile mutants, the Candida spot was spread to increase the 
counter’s ability to see through the dark spot. Additionally, larger 100mm plates were utilized in 
order to better allow for the spreading of the spot. Finally, we validated our methods using both 
known Candida mutants lacking virulence factors as well as the antifungal drug fluconazole.  
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Materials and Methods 
Strains, Media and Growth Conditions 
The mutant C. elegans strain fer-1 was obtained from the Caenorhabditis Genetics Center (MN) 
and stocks were maintained on nematode growth medium (NGM) on Escherichia coli OP50. E. 
coli OP50 was cultured overnight in 5mL Luria broth at 37ºC and Candida albicans strains were 
cultured overnight in 3mL YPD at 30ºC. 
Egg Preparation 
After three days of growth on NGM at 20ºC, C. elegans were washed off with M9 buffer, 
transferred to a 15 mL tube and centrifuged at 2000 rpm for 2 min. The supernatant was removed 
by aspiration and 15 mL bleach treatment (15 mL DI water, 5 mL bleach, 2 pellets NaOH) was 
added. The tube was mixed gently by inverting for 3 min then centrifuged at 3000 rpm for 2 min. 
The supernatant was removed by aspiration, 15mL of M9 were added and the suspension was 
centrifuged once more at 3000 rpm for 2 min. The supernatant was again aspirated and then 
resuspended in M9 to obtain about 30 eggs/5 μl. 
Dar Assay 
Desired Candida strains and E. coli were grown overnight. 200μl of Candida cultures and 1.5mL 
of E. coli culture were centrifuged at full speed for 1 min in a microcentrifuge, washed twice 
with sterile water, and resuspended to obtain Candida cultures of 10 mg/mL and E. coli of 200 
mg/mL. NGM plates were spotted with a mixture of 10μl of 50 mg/mL streptomycin, 7μl sterile 
water, 2.5μl E.coli and 0.5μl of Candida for each Candida strain in triplicate. C. elegans eggs 
were prepared and distributed on the plates. The number of worms showing the Dar phenotype as 
previously described (Jain, 2009) was counted and the percentage was calculated for days 3,4, 
and 5.  
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Pathogenesis Survival Assay 
Desired Candida strains and E. coli were grown overnight. 200μl of Candida cultures and 1.5mL 
of E. coli culture were centrifuged at full speed for 1 min in a microcentrifuge, washed twice 
with sterile water, and resuspended to obtain Candida cultures of 10 mg/mL and E. coli of 200 
mg/mL. NGM plates were spotted with a mixture of 1 μl of 50 mg/mL streptomycin, 7μl sterile 
water, 2.5μl E.coli and 0.5μl of Candida for each Candida strain in triplicate. N2 C. elegans eggs 
were prepared and distributed on 6cm NGM agar plates, and the survival of the worms was 
monitored by counting the live worms, dead worms, and worms on the rim of the plate each day. 
Worms were transferred to new plates every other day to isolate the original generation only, and 
overnight cultures were prepared for the next food spot on the same day as transferring. On days 
opposite transferring and starting overnight cultures, plates were spotted and incubated overnight 
at 30 ºC. This process was continued until no worms were left alive. Survival of worms was 
plotted using SSPS software and the p-values and chi
2
 values were determined using the program 
to determine statistical significance between infected and uninfected C. elegans.  
Survival Assay Optimization 
Alterations to the pathogenesis survival assay were tested by using fer-1 C. elegans instead of the 
wildtype N2 strain, spreading the food spot of E. coli and C. albicans with a large pick after 
overnight incubation and before transferring worms, testing on large 10cm agar plates instead of 
small 6cm plates, lengthening the time between transfers to three to four days, and altering the 
concentration of C. albicans in the food spot. 
Survival Assay Validation 
The optimized survival assay was performed with known avirulent C. albicans mutants, 
cph1Δ/Δ, efg1Δ/Δ and cph1Δ/Δefg1Δ/Δ. The assay was then performed with wildtype SC5314 
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Candida in the presence of fluconazole. Using a fluconazole stock solution of 0.5 mg/mL, 
concentrations of 50μM, 100μM, and 150μM were created in DMSO. The fluconazole solution 
replaced 5μL of water within the food spot.  
C. elegans RNA Extraction 
100 worms were picked off of agar plates infected with C. albicans and put in ice cold M9 in a 
1.5mL tube. Worms were washed off of two plates infected with C. albicans and one uninfected 
plate with M9 buffer. Worms washed off were spun at 3000 rpm for 5 min. and transferred to a 
1.5mL tube. All tubes were spun at 13,000 rpm for 1 min. 100µl Trizol was added, mixed well, 
and incubated at RT for 10 min. Five freeze-thaw cycles with liquid nitrogen and a 37ºC water 
bath were done until no intact bodies were left. 50µl chloroform was added, tubes were mixed, 
and spun at 14,000 rpm for 20 min. at 4ºC. Supernatants were transferred to new tubes, 6µl 
glycogen was added, mixed well, and then mixed with 1 volume of isopropanol. Tubes were 
spun at 14,000 rpm for 20 min. at 4ºC to pellet RNA. Supernatants were removed and the pellets 
washed in 100µl ethanol. Tubes were spun at 7,500rpm for 5 min. at 4ºC. Ethanol was removed 
and pellet was left to air dry for 5 min. RNA pellet was resuspended in 10µl Nuclease-free water. 
RNA concentration was measured with NanoDrop2000. 
RT-PCR 
4µl C. elegans RNA was mixed with 4µl qScript cDNA SuperMix and 2µl Nuclease-free water. 
Tubes were incubated at 25ºC for 5 min., 42ºC for 30 min., and 85ºC for 5 min. cDNA 
concentrations were measured with NanoDrop2000 and 3.5µl cDNA was mixed with 2.5µl 
buffer, 2µl dNTPs, 0.143µl Taq polymerase and 17.86µl Nuclease-free water. cDNA was 
amplified by the following PCR steps: 95ºC for 2 min., 94ºC for 15 sec., 55ºC for 30 sec., 72ºC 
for 1 min, 30 more cycles of those four steps, 72ºC for 10 min., hold at 4ºC. Agarose (1.5%) was 
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added to 150mL 1x TBE running buffer and heated until the mixture dissolved. 10μL ethidium 
bromide was added.  The gel was poured and left to dry. 1x loading dye was added to PCR 
samples, and 15μL of samples were loaded. The gel was run for two hours at 120V.  
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Results 
Establishing fer-1 as a replacement for N2 
In order to develop a simpler, less labor-intensive survival assay, we hypothesized that 
infertile C. elegans mutants fer-1 and fer-15 would allow us to transfer worms less frequently. 
These worms are infertile at 25°C because a mutation in their spermatids prevents them from 
penetrating oocytes, which significantly reduces problems with eggs or larvae (Achanzar 1997).  
The Dar Assay 
To reinforce that fer-1 behaves like N2 wildtype worms in all respects except for 
fertilization, the wildtype and mutant strains were analyzed in terms of the Dar phenotype 
previously detected for C. elegans infected with C. albicans (Jain, 2009). N2 and fer-1 worms 
were used in the Dar assay. As seen in Table 1 and Figure 6, both N2 and fer-1 show reduced 
Dar when fed avirulent C. albicans mutants compared to the cognate wildtype. It can also be 
observed that cph1Δ/Δ has a higher percentage of Dar than either efg1Δ/Δ or the double mutant. 
The double mutant causes Dar in the lowest percentage of worms, sometimes zero percent. 
Table 1: The percentage of Dar for C. elegans infected with different strains of C. albicans decreases with C. albicans of 
lowered virulence compared with wildtype. 
The percentage of worms with Dar was calculated by counting the amount of worms with Dar and dividing that by the total live 
worms on the agar plate. Three Dar assays were carried out with four strains of C. albicans so values for the three assays were 
averaged and standard deviation was calculated. *Dar was not observed and counted on Day 3 for Assay 3 so two values were 
averaged. Panel A was done with N2 worms (p=1.59x10-6), Panel B was done with fer-1(p=1.46x10-6). 
A 
Day caf2-1 cph1Δ/Δ efg1Δ/Δ cph1 Δ/Δefg1Δ/Δ 
3* 62%  +/- 9 35%  +/- 19  9%  +/- 1  1%  +/- 1  
4 72%  +/- 15  35%  +/- 15  10%  +/- 0  3%  +/- 3  
5 84%  +/- 14  29%  +/- 6 20%  +/- 5 4%  +/- 2  
B 
Day caf 2-1 cph1Δ/Δ efg1Δ/Δ cph1Δ/Δefg1Δ/Δ 
3 46 +/- 4 49 +/ 12 8 +/- 3 0 +/- 0 
4 90 +/- 9 89 +/ 21 22 +/ 2 7 +/- 3 
5 100 +/- 0 88 +/ 14 25 +/- 6 11 +/- 4 
 
26 
 
 
A    B  
Figure 6: Mutant C. albicans elicit less Dar in C. elegans than wildtype. 
Average percentages of the three Dar assays for Day 4 were graphed with the previously identified avirulent strains of C. 
albicans. Panel A Dar assay was performed with N2 wildtype worms, Panel B Dar assay with fer-1. 
 
Optimizing the Survival Assay 
To measure the lifespan of worms exposed to C. albicans, the infected population, 60 N2 
worms, must be separated from their progeny daily. This process must be continued every day 
until the worms succumb, and is lengthy and time-consuming. In addition to using fer-1, other 
alterations to streamline the assay were attempted and instituted if useful. The optimization 
protocol’s possible stepwise experimental solutions are presented in Figure 7. Using infertile 
mutants and the optimization steps allowed for the transfer of worms every three to four days. 
 
Figure 7: Survival Assay Optimization Process 
0%
20%
40%
60%
80%
100%
wt cph1Δ/Δ efg1Δ/Δ cph1 Δ/Δ 
efg1Δ/Δ 
N2 
0%
20%
40%
60%
80%
100%
wt cph1Δ/Δ efg1Δ/Δ cph1Δ/Δ 
efg1Δ/Δ 
fer-1 
27 
 
The survival of the two mutant strains, both fer-1 and fer-15, parallel that of N2 wildtype 
worms when infected with C. albicans – worms fed C. albicans die more quickly as shown in 
Figure 8 (p = 0.000) (Pukkila-Worley, 2011). The mutant strains behave comparably to wildtype 
except that their lifespan is slightly shorter under optimal conditions, feeding on E. coli 
attenuated with streptomycin. In optimizing the new survival assay, fer-1 was the more reliable 
strain – the fer-15 was leaky as a result of any slight derivation from the restrictive temperature. 
For example, room temperature when transferring worms would allow them to lay eggs which 
interfered with the survival assay. The life span analysis of fer-15 was similar to that of fer-1 
(data not shown, chi
2
=72, p=0.000).  
 
Figure 8:  Fer-1 C. elegans mutants survive longer when they are not fed C. albicans. 
The day of the survival assay is indicated on the x-axis and the percentage of C. elegans alive on that day is indicated on the y-
axis. Green lines indicate worms fed only dead E. coli (“uninfected”) and blue lines represents “infected” worms fed live C. 
albicans in addition to dead E. coli. For all assays, n=60 (chi2 = 51.313, p = 0.000). 
 
In order to determine if fer-1 reacted similarly to N2 in response to known avirulent 
mutants, validating the altered survival assay, two mutant survival assays were performed 
(Figure 9). In this case, the double mutant cph1Δ/Δefg1Δ/Δ was avirulent (Figure 9A). Efg1Δ/Δ 
showed reduced virulence compared to wildtype. Interestingly, cph1Δ/Δ showed very similar 
results to the wildtype strain. These data are similar to those of N2, indicating that the sterile 
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mutants are parallel to N2 and are an appropriate substitute. Furthermore, the degree of 
pathogenesis between the mutants in the two strains of C. elegans match pathogenicity analyses 
comparing wildtype C. albicans to potentially avirulent mutants in the mouse model (Lo, 1997).  
The second mutant validation survival assay (Figure 9B) revealed no noticeable 
difference between the wildtype SN250 strain and the mutants zcf15Δ/Δ and orf19.1219Δ/Δ. The 
products of these two genes have previously been established as components of the C. albicans 
pathogenesis pathways using the Dar assay as a measure of pathogenicity (Pastor, 2010). 
 
 
 
Figure 9: Validation of mutant survival assay with known C. albicans mutants with reduced virulence. 
The day of the assay is indicated on the x-axis and the percentage of C. elegans alive on that day is indicated on the y-axis. The 
lines represent the percentage of C. elegans alive on that day is indicated on the y-axis.  A. The blue line represents the 
percentage living on agar plates with C. albicans cph1Δ/Δ, the green line represents plates with efg1Δ/Δ and the tan line 
represents plates with cph1Δ/Δ efg1Δ/Δ (chi2 = 63.151, p = 0.000). B. The blue line represents plates with wildtype C. albicans 
strain SN250, the green line represents plates with zcf15Δ/Δ, and the tan line represents plates with orf19.12.19Δ/Δ (chi2 =10.759, 
p=0.005). 
 
As a result of growing the C. albicans for three or four days at a time, the food spot 
overgrew and was difficult to see through. This made getting an accurate count of worms 
difficult. In order to increase visibility through the spot, three different techniques were used, as 
detailed in the assay optimization flowchart, Figure 7. First, the food spot was spread over a 
wider area on the plate with a blunt wire pick before transferring worms onto the plate. Another 
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technique employed was the use of 10 cm plates instead of 5 cm plates. These two techniques 
were tested both individually and together by spotting plates, placing them in the 30°C incubator 
overnight, spreading the appropriate plates the next day, and then putting the plates in the 25°C 
incubator for four days – mimicking the time between transfers. After four days, the plates were 
removed from the incubator and observed. The spread 10 cm plate had the most transparent spot. 
Figure 10 shows both the original and implemented techniques after four days at 25°C both as a 
plate on the bench and under the microscope, zoomed in on the spot. C. elegans worms in the 
spot are marked by arrows. Because of the increased transparency of the spot, spreading and 10 
cm plates were used in all future assays. 
 
 
Figure 10: Opacity of the C. albicans food spot 
From left to right, day 1 of the plate, day 1 under a dissecting microscope at 5X, day 5 of the plate, day 5 under a dissecting 
microscope at 5X. The top row is the 5 cm plate with an un-spread spot. The bottom row is a 10 cm plate, with the food spot 
spread out. White arrows indicate C. elegans. 
 
In order to increase visibility of the worms further, decreased concentrations of C. 
albicans were used in the food spot. The three concentrations used were 10 mg/mL (original), 5 
mg/mL and, 2.5 mg/mL. As can be seen in Figure 11, there was no significant difference in the 
life span of the worms on the different concentrations. From observation, the spot was no more 
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opaque in the 2.5 mg/mL plates as the 10 mg/mL plates, as depicted in Figure 10. Worms in the 
Candida spot are clearly visible, and the spot itself is transparent, whether viewed with the naked 
eye or under a microscope. Thus, a different concentration of C. albicans was not implemented 
in the new survival assay optimized for the infertile C. elegans mutants. 
 
Figure 11: Survival Assay to Optimize of C. albicans concentration reveals no significant difference in infection with 
 C. albicans at 10, 5 and 2.5mg/mL 
The day of the assay is indicated on the x-axis and the percentage of C. elegans alive on that day is indicated on the y-axis. The 
blue line represents the percentage living on agar plates with 0.5µl of 10 mg/mL C. albicans, the green line represents plates with 
0.5µl of 5 mg/mL and the tan line represents plates with 0.5µl of 2.5 mg/mL (Chi2 = 0.579, p = 0.749). 
 
Fer-1’s response to fluconazole 
To validate that fer-1 worms respond to antifungal drugs in the survival assay like 
wildtype N2 worms, titrations of fluconazole were incorporated into the food spot. Worms given 
150 µg/mL, 100 µg/mL, and 50 µg/mL of fluconazole when infected with C. albicans were 
compared with worms not given any drug, depicted in Figure 12. Overall, the worms lived 
longest on the 50 µg/mL fluconazole, with the exception of a couple of worms at the end of the 
survival. Not only did worms live slightly longer in the presence of fluconazole, but the Candida 
was visibly less pathogenic. It became lighter in color, clumpier, and did not form a uniform 
lawn on the agar. 
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Figure 12: Survival assay for the titration of fluconazole as an antifungal drug 
The day of the assay is indicated on the x-axis and the percentage of C. elegans alive on that day is indicated on the y-axis. The 
blue line represents the percentage of worms living on control plates with 0 µg/mL fluconazole, the green line represents plates 
with 50 µg/mL fluconazole, the yellow line represents plates with 100 µg/mL fluconazole, and the purple line represents plates 
with 150 µg/mL (Chi2 = 12.784, p = 0.005) 
 
Peptides of the C. elegans innate immune system  
In order to further validate that the survival assay is measuring the pathogenesis of the 
fungus and not other factors such as contamination or dehydration, semi-quantitative RT-PCR 
was performed on both C. elegans infected with Candida and uninfected, living only on dead E. 
coli. The mRNA transcripts amplified, the genes encoding NLP29, NLP31, ABF2, IRG1 and 
HSP16.41, were chosen because they have been found to be upregulated during C. elegans 
infection. NLP29 and NLP31 are antimicrobial peptides (AMPs) known to be a part of the C. 
elegans immune response as a part of the MAP kinase pathway, and can be turned on by D. 
coniospora infection (Pujol, 2008). ABF2 is an AMP upregulated in the response against many 
pathogens, but especially upon fungal infection from C. krusei, S. cerevisiae, T. delbrueckii and 
D. hansenii, among others (Kato, 2002). IRG-1 is a host “infection response gene” also a part of 
the MAP kinase pathway and known to be induced by P. aeruginosa infection (Estes, 2010) and 
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HSP16.41 is a heat shock protein implicated in the innate immune response against Salmonella 
enterica (Tenor, 2008). 
As seen in Figure 13, the samples from infected worms had significantly darker bands 
from AMP transcripts upon electrophoresis compared with uninfected worms. The actin control 
was transcribed at the same level by the two groups of worms (ACT1) but the AMP transcripts 
for NLP29, NLP31, and ABF2 seemed to be upregulated in infected worms. There is only a very 
faint band in the infected lane of HSP16.41, and IRG1 did not appear to be upregulated upon 
infection (data not shown). These data suggest that these two proteins may not be a significant 
part of the innate immune system pathways, but that NLP29, NLP31 and ABF2 are turned on in 
these pathways. 
      
Figure 13: RT-PCR of C. elegans infected with C. albicans versus uninfected shows higher levels of antimicrobial peptide 
RNA upon infection 
Gel electrophoresis of cDNAs after reverse transcription from RNAs extracted from uninfected and infected worms. RT minus is 
Actin RNA before reverse transcription. NLP29, NLP31 and ABF2 are antimicrobial peptides and HSP16.41 is a Heat Shock 
Protein. ACT1 is the Actin gene 1 transcribed from cDNA.  
HSP 16.41 
Uninfected   Infected Uninfected   Infected 
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Discussion 
 We have demonstrated that the use of sterile C. elegans is a viable alternative to wildtype 
for analyzing the lifespan of worms infected with C. albicans. Fer-1 mutants were used because 
they do not produce viable eggs. This means that with the use of sterile worms, transferring the 
original infected worms away from their progeny, which is necessary to measure the life-span, 
was not necessary. The modified protocol requires transfer of worms to agar plates when the C. 
albicans lawn has grown too thick to see the worms to count which are alive and dead, 
approximately every four days. In order to maximize the amount of time between transfers, large 
10cm agar plates were used which allowed the food spot out to be as spread out as possible. 
 Our studies show that fer-1 is a suitable substitute for wildtype N2 worms on several 
accounts. First, the sterile worms have a comparable lifespan to wildtype, for both worms 
infected with C. albicans in addition to uninfected control worms. Secondly, when infected with 
previously identified avirulent mutants such as cph1Δ/Δefg1Δ/Δ, cph1Δ/Δ and efg1Δ/Δ, fer-1 
Dar patterns matched those of N2. These data correctly correlate with the mutants missing 
virulence factors implicated in the formation of hyphae. In the survival assay with the same three 
mutants, the worms on cph1Δ/Δefg1Δ/Δ lived the longest and their lifespan matched that of 
uninfected worms. The worms on efg1Δ/Δ were similar to that of uninfected worms, but the 
lifespan of these worms was slightly shorter. In the survival curve using cph1Δ/Δ, worms died 
faster than the other two mutant strains and appeared sicker. They moved slowly if at all, and had 
distended abdomens. This further validated the assay because the fer-1 survival with these 
mutants matches similar studies in mice (Lo, 1997). Thus, new avirulent mutants can be 
discovered using this pathogenesis survival assay in a mutant screen, in order to give rise to 
genes that are a part of Candida pathogenesis pathways. The mutant screen would be easier and 
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less labor-intensive than a screen using wildtype C. elegans or a mammal such as mice as a result 
of the optimized survival assay. The C. elegans only live for about two to three weeks, while 
mice live much longer, which will allow for more screens to take place in a given amount of 
time, with a given amount of technicians, time and money. 
 While a lifespan of two to three weeks is simpler and more efficient than a longer 
lifespan, evaluating the pathogenicity of C. albicans in just one week is less reliable. The Dar 
assay, observing enlarged anal regions in worms infected with C. albicans, is five days long, and 
does not give a large scope of the effects of the infection like a survival assay does. As seen in all 
of the survival curves in this study, there is a large drop-off of live worms between day five and 
ten, marking a switch in the Candida infection thriving and the worms’ immune systems 
succumbing to the disease. The shorter Dar assay may not take this event into account. 
Furthermore, it is quite unambiguous and objective to determine if a worm is alive or dead, but 
the Dar phenotype is much more subjective to observe. Sometimes the Dar phenotype can be 
difficult to see, especially for worms within the Candida lawn, and there are often worms that are 
“borderline,” and their anal region could equally be deformed or normal. Therefore, our data and 
observations propose this survival assay a much more reliable measure of C. albicans 
pathogenesis. 
It was found that leaving sterile worms out of the 25 ºC incubator for more than a few 
minutes at a time exacerbated the issue of the leaky fer-1 and fer-15 mutations. It is very 
important to know what the precise room temperature of a lab is, rather than generalizing what 
the room temperature is approximately supposed to be. One problem with fer-1 and fer-15 is that 
the sterility mutation was leaky. Slight changes in temperature, even the short time to transfer, 
caused fer-15 to lay eggs. While there were not many larvae, it caused enough of a problem to 
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discontinue its use in further studies. Fer-1 was leaky from the time the eggs were plated, in 
order to begin a survival assay, until the first transfer. After the first transfer, there were no more 
eggs being laid. During the time before the first transfer, any larvae found were killed, allowing 
the first generation to still be distinguished from newer ones.  
 The concentrations of antifungal drug used in the fluconazole survival assay ranged from 
a control plate (0uM) to 150uM in 50uM increments. The 50uM concentration of fluconazole 
was the most effective for maintaining the health of the worms. A contributing factor may have 
been that there was some contamination on the 100 and 150uM plates. Once a transfer occurred, 
the contamination disappeared.  
 Even though there were higher concentrations used than 50uM, they appeared to not be 
as effective in increasing the survival of the worms. It is probable that the death rate of the 
worms on food spots containing 100 and 150uM fluconazole was influenced by the harmful 
effects of fluconazole on the host. Fluconazole attacks ergosterol, which is very similar to 
cholesterol – contained in animal cell membranes. These concentrations of fluconazole may have 
simply been too high for the 1mm nematodes. In order to account for this in future studies, a 
survival assay giving worms only the drug should be completed to determine the drug’s natural 
effects on the worms’ lifespan. In order to use this assay for other potential drugs, similar assays 
must be completed. First, a survival must be carried out with only the possible antifungal drug to 
establish if it negatively affects worms, and a second with C. albicans and the possible antifungal 
drug to determine its ability to either halt or prevent infections in C. elegans. Another useful step 
would be to apply the optimum concentration of drug before infecting the worms, at the same 
time as infecting the worms (the option used in this study) and after infecting the worms, and 
evaluate various survival rates. 
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 One of the results seen in the survival assay with fluconazole was that the C. albicans did 
not die, but became a significantly different consistency – clumpier and darker. Fluconazole is 
fungistatic which means that it will not kill the fungus; it inhibits its growth and replication. The 
change in phenotype was thought to be due to the inhibited growth but not death of the C. 
albicans. There are fungicidal – fungus killing – antifungal medications, but these tend to be 
more toxic to the host, such as Amphotericin B. One problem with fungistatic medications is that 
the small amount of fungus left over can proliferate and potentially become resistant to the 
antifungal drug or compound. This has been a serious problem with antifungal drugs, because 
more and more strains of C. albicans and other fungi are becoming resistant to fungistatic 
antifungal medications.  
 Semi-quantitative RT-PCR was performed on infected and uninfected C. elegans in order 
to verify that an antifungal immune response was taking place upon infection with C. albicans. 
As depicted by the RT minus bands, there was some genomic DNA contamination in the RNA 
extraction. Because some DNA was isolated as well, the levels of the genes amplified by PCR 
are not as high as the bands are bright – in other words, the brightness of the “RNA” before 
reverse transcription bands must be subtracted from the RT-PCR bands.  This makes for a less 
drastic difference in viewing the upregulation of transcripts of antimicrobial peptides during 
fungal infection. However, the cDNAs of the uninfected and infected Actin-1 gene are identical, 
indicating that in an unrelated gene, the amount of mRNA expressed was the same for both 
uninfected and infected worms, and giving validity to the experiment. 
There were three AMP transcripts that seemed to be upregulated upon infection with C. 
albicans: NLP-29, NLP-31, and ABF-2. This data indicates that these peptides may have a 
distinct role in the innate immune system against fungal infection within C. elegans, elucidating 
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a better understanding of those particular molecular pathways. There was no IRG-1, a host 
response gene (data not shown), and very little HSP16.41 mRNA present in order to make cDNA 
during RT-PCR. This may indicate that not only are these proteins not upregulated during 
infection, but are also not produced at this particular time in the life cycle of the nematodes 
(RNA isolated at 72 hours). This procedure has been done with wildtype N2 worms and no 
conclusive upregulation of AMP transcripts was detected (Luca Issi, personal communication). 
Further experiments must be done to test both N2 worms and fer-1 mutants at earlier time points 
than at day 3, or 72 hours post-infection, to definitively determine if and when these AMP 
transcripts are produced. Regardless, these findings are important because the immune system of 
C. elegans is very similar to the innate immune system of humans, with comparable if not 
homologous pathways. Therefore, the more information gained about the C. elegans immune 
system, the more knowledge gained about the innate immune system in humans. 
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Appendix 
In this appendix are all of the raw data worksheets used to mark live, dead or “edge” 
worms throughout survival experiments. Worms that are marked by “edge” died for reasons 
other than Candida infection, such as dehydration on the edge of the agar plate or digging into 
the agar and not resurfacing. The worksheets are in this order: fer-1 and fer-15 trials to establish 
lifespan when infected and uninfected, validation with known avirulent mutants cph1∆/∆, 
efg1∆/∆ and cph1∆/∆efg1∆/∆, validation with potential avirulent mutants zcf15∆/∆ and 
orf19.1219∆/∆ compared with wildtype SN250, the Candida concentration titration, and the 
fluconazole concentration titration.
 
 
 
UNINFECTED Strain: Fer1
Date Task Alive Edge Dead Alive Edge Dead
Day -3 start cultures (E.coli)
Day -2 egg prep + spotting, start cultures
Day -1 spotting
Day 0 10/31/2011 transfer same # (20) of worms, 25 0 0 26 0 0
Day 1 11/1/2011 count (edge v. dead) 13 7 5 19 4 3
Day 2 11/2/2011 count (edge v. dead), start cultures 13 0 0 19 0 0
Day 3 11/3/2011 count (edge v. dead), spot 12 0 1 19 0 0
Day 4 11/4/2011 transfer (edge v. dead*) 12 0 0 19 0 0
Day 5 11/5/2011 count (edge v. dead) 11 1 0 17 1 1
Day 6 11/6/2011 count (edge v. dead) start cultures 10 0 1 17 0 0
Day 7 11/7/2011 count (edge v. dead), spot 10 0 0 17 0 0
Day 8 11/8/2011 transfer (edge v. dead) 6 1 3 6 0 11
Day 9 11/9/2011 count (edge v. dead), start cultures 5 0 1 3 0 3
Day 10 11/10/2011 count (edge v. dead), spot 0 0 5 0 0 3
Plate A Plate B
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INFECTED Strain: Fer1
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 start cultures (E.coli)
Day -2 egg prep + spotting, start cultures
Day -1 spotting
Day 0 10/31/2011 transfer same # (20) of worms, 15 0 0 23 0 0 20 0 0
Day 1 11/1/2011 count (edge v. dead) 9 3 3 16 2 5 12 0 8
Day 2 11/2/2011 count (edge v. dead), start cultures 9 0 0 15 0 1 9 1 2
Day 3 11/3/2011 count (edge v. dead), spot 5 1 3 11 1 3 6 0 3
Day 4 11/4/2011 transfer (edge v. dead*) 4 0 1 8 3 0 3 1 2
Day 5 11/5/2011 count (edge v. dead) 3 0 1 3 2 3 3 0 0
Day 6 11/6/2011 count (edge v. dead) start cultures 2 0 1 3 0 0 2 0 1
Day 7 11/7/2011 count (edge v. dead), spot 2 0 0 2 0 1 2 0 0
Day 8 11/8/2011 transfer (edge v. dead) 1 0 1 1 0 1 2 0 0
Day 9 11/9/2011 count (edge v. dead), start cultures 1 0 0 1 0 0 1 0 1
Day 10 11/10/2011 count (edge v. dead), spot 1 0 0 1 0 0 1 0 0
Day 11 11/11/2011 transfer (edge v. dead) 0 0 1 0 0 1 0 0 1
Plate A Plate B Plate C
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UNINFECTED Strain: Fer-1
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 start cultures (E.coli)
Day -2 egg prep + spotting, start cultures
Day -1 spotting
Day 0 12/1/2011 transfer same # (20) of worms, 20 0 0 20 0 0 20 0 0
Day 1 12/2/2011 count (edge v. dead) 19 0 1 20 0 0 20 0 0
Day 2 12/3/2011 count (edge v. dead), start cultures 18 1 0 19 0 1 19 0 1
Day 3 12/4/2011 count (edge v. dead), spot 18 0 0 14 5 0 18 1 0
Day 4 12/5/2011 transfer (edge v. dead*) 16 1 1 14 0 0 18 0 0
Day 5 12/6/2011 count (edge v. dead) 14 0 2 14 0 0 18 0 0
Day 6 12/7/2011 count (edge v. dead) start cultures 14 0 0 12 2 0 18 0 0
Day 7 12/8/2011 count (edge v. dead), spot 13 0 1 10 1 1 17 0 1
Day 8 12/9/2011 transfer (edge v. dead) 13 0 0 9 0 1 13 1 3
Day 9 12/10/2011 count (edge v. dead), start cultures 8 0 5 4 0 5 11 0 2
Day 10 12/11/2011 count (edge v. dead), spot 5 2 1 3 0 1 11 0 0
Day 11 12/12/2011 transfer (edge v. dead) 3 0 2 1 0 2 10 0 1
Day 12 12/13/2011 count (edge v. dead), start cultures 3 0 0 1 0 0 3 0 7
Day 13 12/14/2011 count (edge v. dead), spot 2 0 1 0 0 1 1 0 2
Day 14 12/15/2011 transfer (edge v. dead) 1 0 1 0 0 0 1 0 0
Day 15 12/16/2011 count (edge v. dead) 1 0 0 0 0 0 0 0 1
Day 16 12/17/2011 count (edge v. dead) start cultures 0 0 1 0 0 0 0 0 0
Plate A Plate B Plate C
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INFECTED Strain: Fer-1
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 start cultures (E.coli)
Day -2 egg prep + spotting, start cultures
Day -1 spotting
Day 0 12/1/2011 transfer same # (20) of worms, 20 0 0 20 0 0 20 0 0
Day 1 12/2/2011 count (edge v. dead) 19 0 1 19 0 1 19 0 1
Day 2 12/3/2011 count (edge v. dead), start cultures 19 0 0 16 0 3 16 0 3
Day 3 12/4/2011 count (edge v. dead), spot 7 0 12 7 0 9 1 0 15
Day 4 12/5/2011 transfer (edge v. dead*) 3 0 4 3 0 4 0 0 1
Day 5 12/6/2011 count (edge v. dead) 3 0 0 2 0 1 0 0 0
Day 6 12/7/2011 count (edge v. dead) start cultures 3 0 0 1 0 1 0 0 0
Day 7 12/8/2011 count (edge v. dead), spot 2 0 1 1 0 0 0 0 0
Day 8 12/9/2011 transfer (edge v. dead) 2 0 0 1 0 0 0 0 0
Day 9 12/10/2011 count (edge v. dead), start cultures 1 0 1 0 0 1 0 0 0
Day 10 12/11/2011 count (edge v. dead), spot 1 0 0 0 0 0 0 0 0
Day 11 12/12/2011 transfer (edge v. dead) 1 0 0 0 0 0 0 0 0
Day 12 12/13/2011 count (edge v. dead), start cultures 0 0 1 0 0 0 0 0 0
Plate A Plate B Plate C
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UNINFECTED Strain: Fer-15 on E.coli
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -1 9/29/2011 start cultures
Day 0 9/30/2011 egg prep + spotting
Day 1 10/1/2011 start cultures
Day 1.5 10/2/2011 spotting and counting
Day 2 10/3/2011 transfer same # of worms, start culture 30 0 0 30 0 0 30 0 0
Day 3 10/4/2011 spotting, count (edge v. dead) 29 1 0 30 0 0 28 0 2
Day 4 10/5/2011 transfer, (edge v. dead*), start culture 28 1 1 29 1 0 24 2 2
Day 5 10/6/2011 spotting, count (edge v. dead) 25 1 2 27 1 1 24 0 0
Day 6 10/7/2011 transfer, (edge v. dead*), start culture 25 1 2 19 1 7 23 0 1
Day 7 10/8/2011 spotting, count (edge v. dead) 24 0 1 19 0 0 24 0 1
Day 8 10/9/2011 transfer, (edge v. dead*), start culture 24 0 0 19 0 0 21 0 3
Day 9 10/10/2011 spotting, count (edge v. dead) 24 0 0 18 0 1 21 0 0
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INFECTED Strain: Fer-15 on E. coli and Candida
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -1 9/29/2011 start cultures
Day 0 9/30/2011 egg prep + spotting
Day 1 10/1/2011 start cultures
Day 1.5 10/2/2011 spotting and counting 12 1 0 11 2 1 31 1 0
Day 2 10/3/2011 transfer same # of worms, start culture 9 0 3 11 2 0 18 5 8
Day 3 10/4/2011 spotting, count (edge v. dead) 7 0 2 4 0 7 8 2 8
Day 4 10/5/2011 transfer, (edge v. dead*), start culture 2 2 3 2 0 2 7 0 1
Day 5 10/6/2011 spotting, count (edge v. dead) 1 0 1 2 0 0 4 2 0
Day 6 10/7/2011 transfer, (edge v. dead*), start culture 0 0 1 2 0 0 4 0 0
Day 7 10/8/2011 spotting, count (edge v. dead) 0 0 0 2 0 0 4 0 0
Day 8 10/9/2011 transfer, (edge v. dead*), start culture 0 0 0 2 0 0 1 0 3
Day 9 10/10/2011 spotting, count (edge v. dead) 0 0 0 1 0 0 0 0 1
Day 10 10/11/2011 transfer, (edge v. dead*), start culture 0 0 0 0 0 0
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UNINFECTED Strain: Fer 15
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 start cultures (E.coli)
Day -2 egg prep + spotting, start cultures
Day -1 spotting
Day 0 11/4/2011 transfer same # (20) of worms, 20 0 0 20 0 0 20 0 0
Day 1 11/5/2011 count (edge v. dead) 20 0 0 20 0 0 6 6 0
Day 2 11/6/2011 count (edge v. dead), start cultures 20 0 0 19 0 1 5 1 0
Day 3 11/7/2011 count (edge v. dead), spot 20 0 0 19 0 0 3 6 0
Day 4 11/8/2011 transfer (edge v. dead*) 20 0 0 17 2 0 5 1 0
Day 5 11/9/2011 count (edge v. dead) 19 1 0 17 0 0 4 0 1
Day 6 11/10/2011 count (edge v. dead) start cultures 13 1 5 14 0 3 4 0 0
Day 7 11/11/2011 count (edge v. dead), spot 10 0 3 11 0 3 3 0 1
Day 8 11/12/2011 transfer (edge v. dead) 6 1 4 7 1 3 3 0 0
Day 9 11/13/2011 count (edge v. dead), start cultures 4 0 2 4 0 3 2 0 1
Day 10 11/14/2011 count (edge v. dead), spot 3 0 1 1 0 3 1 0 1
Day 11 11/15/2011 transfer (edge v. dead) 3 0 0 0 0 1 0 0 1
Day 12 11/16/2011 count (edge v. dead), start cultures 1 0 2 0 0 0 0 0 0
Day 13 11/17/2011 count (edge v. dead), spot 0 0 1 0 0 0 0 0 0
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INFECTED Strain: Fer 15
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 start cultures (E.coli)
Day -2 egg prep + spotting, start cultures
Day -1 spotting
Day 0 11/4/2011 transfer same # (20) of worms, 20 0 0 20 0 0 20 0 0
Day 1 11/5/2011 count (edge v. dead) 20 0 0 14 0 1 18 2 0
Day 2 11/6/2011 count (edge v. dead), start cultures 20 0 0 14 0 0 16 4 0
Day 3 11/7/2011 count (edge v. dead), spot 20 0 0 12 2 0 20 0 0
Day 4 11/8/2011 transfer (edge v. dead*) 20 0 0 12 0 0 13 4 3
Day 5 11/9/2011 count (edge v. dead) 18 0 2 11 1 0 11 0 2
Day 6 11/10/2011 count (edge v. dead) start cultures 12 1 5 9 1 1 10 0 1
Day 7 11/11/2011 count (edge v. dead), spot 11 0 1 9 0 1 10 0 0
Day 8 11/12/2011 transfer (edge v. dead) 5 0 6 6 0 3 6 1 3
Day 9 11/13/2011 count (edge v. dead), start cultures 3 0 2 3 0 3 2 2 2
Day 10 11/14/2011 count (edge v. dead), spot 3 0 0 3 0 0 1 0 1
Day 11 11/15/2011 transfer (edge v. dead) 1 0 2 2 0 1 1 0 0
Day 12 11/16/2011 count (edge v. dead), start cultures 0 0 1 1 0 1 0 0 1
Day 13 11/17/2011 count (edge v. dead), spot 0 0 0 0 0 1 0 0 0
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Strain: fer-1 on cph
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 2/7/2011 start cultures (E.coli)
Day -2 2/8/2011 egg prep + spotting, start cultures
Day -1 2/9/2011 spotting
Day 0 2/10/2011 transfer same # of worms, start culture 20 0 0 20 0 0 20 0 0
Day 1 2/11/2011 spotting, count (edge v. dead) 17 3 0 20 0 0 18 2 0
Day 2 2/12/2011 transfer, (edge v. dead*), start culture 15 1 1 19 0 1 17 1 0
Day 3 2/13/2011 spotting, count (edge v. dead) 13 0 2 17 0 2 16 0 1
Day 4 2/14/2011 transfer, (edge v. dead*), start culture 13 0 0 9 2 6 6 2 8
Day 5 2/15/2011 spotting, count (edge v. dead) 4 2 7 6 0 3 5 0 1
Day 6 2/16/2011 transfer, (edge v. dead*), start culture 2 0 2 2 0 4 4 0 1
Day 7 2/17/2011 spotting, count (edge v. dead) 1 1 0 1 0 1 4 0 0
Day 8 2/18/2011 transfer, (edge v. dead*), start culture 0 0 1 1 0 0 3 0 1
Day 9 2/19/2011 spotting, count (edge v. dead) 0 0 1 2 0 1
Day 10 2/20/2011 transfer, (edge v. dead*), start culture 1 0 1
Day 11 2/21/2011 spotting, count (edge v. dead) 1 0 0
Day 12 2/22/2011 transfer, (edge v. dead*), start culture 0 0 1
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Strain: fer-1 on efg
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 2/7/2011 start cultures (E.coli)
Day -2 2/8/2011 egg prep + spotting, start cultures
Day -1 2/9/2011 spotting
Day 0 2/10/2011 transfer same # of worms, start culture 20 0 0 20 0 0 20 0 0
Day 1 2/11/2011 spotting, count (edge v. dead) 18 0 2 17 3 0 20 0 0
Day 2 2/12/2011 transfer, (edge v. dead*), start culture 17 0 1 17 0 0 20 0 0
Day 3 2/13/2011 spotting, count (edge v. dead) 17 0 0 17 0 0 20 0 0
Day 4 2/14/2011 transfer, (edge v. dead*), start culture 17 0 0 17 0 0 20 0 0
Day 5 2/15/2011 spotting, count (edge v. dead) 15 2 0 16 1 0 18 1 1
Day 6 2/16/2011 transfer, (edge v. dead*), start culture 14 1 0 14 2 0 18 0 0
Day 7 2/17/2011 spotting, count (edge v. dead) 14 0 0 13 1 0 18 0 0
Day 8 2/18/2011 transfer, (edge v. dead*), start culture 13 1 0 13 0 0 13 0 5
Day 9 2/19/2011 spotting, count (edge v. dead) 4 0 9 6 0 7 5 0 8
Day 10 2/20/2011 transfer, (edge v. dead*), start culture 4 0 0 3 0 3 2 0 3
Day 11 2/21/2011 spotting, count (edge v. dead) 1 0 3 0 0 3 1 0 1
Day 12 2/22/2011 transfer, (edge v. dead*), start culture 1 0 0 0 0 1
Day 13 2/23/2011 spotting, count (edge v. dead) 0 0 1
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Strain: fer-1 on cph/efg double
Day Date Task Alive Edge Dead Alive Edge Dead
Day -3 2/7/2011 start cultures (E.coli)
Day -2 2/8/2011 egg prep + spotting, start cultures
Day -1 2/9/2011 spotting
Day 0 2/10/2011 transfer same # of worms, start culture 20 0 0 20 0 0
Day 1 2/11/2011 spotting, count (edge v. dead) 20 0 0 18 0 2
Day 2 2/12/2011 transfer, (edge v. dead*), start culture 18 0 2 18 0 0
Day 3 2/13/2011 spotting, count (edge v. dead) 18 0 0 18 0 0
Day 4 2/14/2011 transfer, (edge v. dead*), start culture 18 0 0 18 0 0
Day 5 2/15/2011 spotting, count (edge v. dead) 17 1 0 17 0 1
Day 6 2/16/2011 transfer, (edge v. dead*), start culture 17 0 0 17 0 0
Day 7 2/17/2011 spotting, count (edge v. dead) 14 3 0 12 4 1
Day 8 2/18/2011 transfer, (edge v. dead*), start culture 12 0 2 9 0 3
Day 9 2/19/2011 spotting, count (edge v. dead) 7 0 5 6 1 2
Day 10 2/20/2011 transfer, (edge v. dead*), start culture 5 0 2 5 0 1
Day 11 2/21/2011 spotting, count (edge v. dead) 3 0 2 5 0 0
Day 12 2/22/2011 transfer, (edge v. dead*), start culture 3 0 0 4 0 1
Day 13 2/23/2011 spotting, count (edge v. dead) 1 0 2 2 1 1
Day 14 2/24/2011 transfer, (edge v. dead*), start culture 0 0 1 0 0 2
Plate B Plate C
50 
 
 
 
Strain: fer-1 on WT SN250
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 1/13/2011 start cultures (E.coli)
Day -2 1/14/2011 egg prep + spotting, start cultures
Day -1 1/15/2011 spotting
Day 0 1/17/2011 transfer same # of worms, start culture 20 0 0 20 0 0 20 0 0
Day 1 1/18/2011 spotting, count (edge v. dead) 16 0 4 19 0 1 19 1 0
Day 2 1/19/2011 transfer, (edge v. dead*), start culture 15 0 1 18 0 1 18 0 1
Day 3 1/20/2011 spotting, count (edge v. dead) 10 0 5 17 0 1 18 0 0
Day 4 1/21/2011 transfer, (edge v. dead*), start culture 7 1 2 15 0 2 16 2 0
Day 5 1/22/2011 spotting, count (edge v. dead) 6 0 1 14 0 1 10 0 6
Day 6 1/23/2011 transfer, (edge v. dead*), start culture 6 0 0 9 0 5 9 0 1
Day 7 1/24/2011 spotting, count (edge v. dead) 6 0 0 9 0 0 9 0 0
Day 8 1/25/2011 transfer, (edge v. dead*), start culture 3 3 0 7 0 2 8 0 1
Day 9 1/26/2011 spotting, count (edge v. dead) 3 0 0 5 0 2 8 0 0
Day 10 1/27/2011 transfer, (edge v. dead*), start culture 3 0 0 3 0 2 6 1 1
Day 11 1/28/2011 spotting, count (edge v. dead) 3 0 0 2 0 1 4 0 2
Day 12 1/29/2011 transfer, (edge v. dead*), start culture 1 0 2 1 0 1 4 0 0
Day 13 1/30/2011 spotting, count (edge v. dead) 1 0 0 0 0 1 2 0 2
Day 14 1/31/2011 transfer, (edge v. dead*), start culture 1 0 0 0 0 0 2 0 0
Day 15 2/1/2011 spotting, count (edge v. dead) 0 0 1 2 0 0
Day 16 2/2/2011 transfer, (edge v. dead*), start culture 0 0 0 2 0 0
Day 17 2/3/2011 spotting, count (edge v. dead) 1 0 1
Day 18 2/4/2011 transfer, (edge v. dead*), start culture 0 0 1
Day 19 2/5/2011 spotting, count (edge v. dead) 0 0 0
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Strain: fer-1 on WT SN250
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 1/13/2011 start cultures (E.coli)
Day -2 1/14/2011 egg prep + spotting, start cultures
Day -1 1/15/2011 spotting
Day 0 1/17/2011 transfer same # of worms, start culture 5 0 0 5 0 0 5 0 0
Day 1 1/18/2011 spotting, count (edge v. dead) 5 0 0 5 0 0 5 0 0
Day 2 1/19/2011 transfer, (edge v. dead*), start culture 5 0 0 5 0 0 5 0 0
Day 3 1/20/2011 spotting, count (edge v. dead) 4 0 1 5 0 0 5 0 0
Day 4 1/21/2011 transfer, (edge v. dead*), start culture 4 0 0 5 0 0 5 0 0
Day 5 1/22/2011 spotting, count (edge v. dead) 4 0 0 5 0 0 5 0 0
Day 6 1/23/2011 transfer, (edge v. dead*), start culture 4 0 0 4 1 0 4 0 1
Day 7 1/24/2011 spotting, count (edge v. dead) 4 0 0 4 0 0 4 0 0
Day 8 1/25/2011 transfer, (edge v. dead*), start culture 3 0 1 3 0 1 3 1 0
Day 9 1/26/2011 spotting, count (edge v. dead) 3 0 0 2 0 1 2 0 1
Day 10 1/27/2011 transfer, (edge v. dead*), start culture 2 1 0 2 0 0 2 0 0
Day 11 1/28/2011 spotting, count (edge v. dead) 1 0 1 2 0 0 1 0 1
Day 12 1/29/2011 transfer, (edge v. dead*), start culture 1 0 0 0 0 2 1 0 0
Day 13 1/30/2011 spotting, count (edge v. dead) 1 0 0 0 0 0 1 0 0
Day 14 1/31/2011 transfer, (edge v. dead*), start culture 0 0 1 1 0 0
Day 15 2/1/2011 spotting, count (edge v. dead) 0 0 0 0 0 1
Day 16 2/2/2011 transfer, (edge v. dead*), start culture 0 0 0
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Strain: fer-1 on zcf 15 -/-
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 1/13/2011 start cultures (E.coli)
Day -2 1/14/2011 egg prep + spotting, start cultures
Day -1 1/15/2011 spotting
Day 0 1/17/2011 transfer same # of worms, start culture 20 0 0 20 0 0 20 0 0
Day 1 1/18/2011 spotting, count (edge v. dead) 14 0 6 18 0 2 20 0 0
Day 2 1/19/2011 transfer, (edge v. dead*), start culture 9 5 0 13 1 4 13 1 6
Day 3 1/20/2011 spotting, count (edge v. dead) 9 0 0 8 0 5 10 0 3
Day 4 1/21/2011 transfer, (edge v. dead*), start culture 9 0 0 5 0 3 9 0 1
Day 5 1/22/2011 spotting, count (edge v. dead) 9 0 0 5 0 0 4 0 5
Day 6 1/23/2011 transfer, (edge v. dead*), start culture 8 0 1 5 0 0 1 0 3
Day 7 1/24/2011 spotting, count (edge v. dead) 8 0 0 5 0 0 1 0 0
Day 8 1/25/2011 transfer, (edge v. dead*), start culture 5 1 2 4 0 1 1 0 0
Day 9 1/26/2011 spotting, count (edge v. dead) 4 0 1 4 0 0 1 0 0
Day 10 1/27/2011 transfer, (edge v. dead*), start culture 3 0 1 2 0 2 1 0 0
Day 11 1/28/2011 spotting, count (edge v. dead) 2 0 1 1 0 1 1 0 0
Day 12 1/29/2011 transfer, (edge v. dead*), start culture 0 0 2 0 0 1 1 0 0
Day 13 1/30/2011 spotting, count (edge v. dead) 0 0 0 0 0 0 0 0 1
Day 14 1/31/2011 transfer, (edge v. dead*), start culture 0 0 0
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Strain: fer-1 on zcf 15 -/-
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 1/14/2011 start cultures (E.coli)
Day -2 1/15/2011 egg prep + spotting, start cultures
Day -1 1/16/2011 spotting
Day 0 1/17/2011 transfer same # of worms, start culture 5 0 0 5 0 0 5 0 0
Day 1 1/18/2011 spotting, count (edge v. dead) 5 0 0 5 0 0 5 0 0
Day 2 1/19/2011 transfer, (edge v. dead*), start culture 5 0 0 5 0 0 5 0 0
Day 3 1/20/2011 spotting, count (edge v. dead) 5 0 0 5 0 0 5 0 0
Day 4 1/21/2011 transfer, (edge v. dead*), start culture 3 0 2 5 0 0 5 0 0
Day 5 1/22/2011 spotting, count (edge v. dead) 3 0 0 5 0 0 4 0 1
Day 6 1/23/2011 transfer, (edge v. dead*), start culture 1 0 2 2 0 3 2 0 2
Day 7 1/24/2011 spotting, count (edge v. dead) 1 0 0 2 0 0 2 0 0
Day 8 1/25/2011 transfer, (edge v. dead*), start culture 1 0 0 1 1 0 2 0 0
Day 9 1/26/2011 spotting, count (edge v. dead) 1 0 0 1 0 0 2 0 0
Day 10 1/27/2011 transfer, (edge v. dead*), start culture 1 0 0 1 0 0 1 0 1
Day 11 1/28/2011 spotting, count (edge v. dead) 0 0 1 0 0 1 1 0 0
Day 12 1/29/2011 transfer, (edge v. dead*), start culture 0 0 0 0 0 0 1 0 0
Day 13 1/30/2011 spotting, count (edge v. dead) 1 0 0
Day 14 1/31/2011 transfer, (edge v. dead*), start culture 1 0 0
Day 15 2/1/2011 spotting, count (edge v. dead) 1 0 0
Day 16 2/2/2011 transfer, (edge v. dead*), start culture 1 0 0
Day 17 2/3/2011 spotting, count (edge v. dead) 1 0 0
Day 18 2/4/2011 transfer, (edge v. dead*), start culture 1 0 0
Day 19 2/5/2011 spotting, count (edge v. dead) 0 0 1
Day 20 2/6/2011 count (edge v. dead), spot 0 0 0
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Strain: fer-1 on ORF 19.1219
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 1/14/2011 start cultures (E.coli)
Day -2 1/15/2011 egg prep + spotting, start cultures
Day -1 1/16/2011 spotting
Day 0 1/17/2011 transfer same # of worms, start culture 20 0 0 20 0 0 20 0 0
Day 1 1/18/2011 spotting, count (edge v. dead) 19 0 1 16 2 2 20 0 0
Day 2 1/19/2011 transfer, (edge v. dead*), start culture 19 0 0 12 3 1 14 6 0
Day 3 1/20/2011 spotting, count (edge v. dead) 18 0 1 12 0 0 14 0 0
Day 4 1/21/2011 transfer, (edge v. dead*), start culture 13 0 5 11 0 1 11 0 3
Day 5 1/22/2011 spotting, count (edge v. dead) 11 0 2 10 0 1 10 0 1
Day 6 1/23/2011 transfer, (edge v. dead*), start culture 9 0 2 8 0 2 6 0 4
Day 7 1/24/2011 spotting, count (edge v. dead) 9 0 0 8 0 0 5 0 1
Day 8 1/25/2011 transfer, (edge v. dead*), start culture 8 1 0 6 0 2 3 0 2
Day 9 1/26/2011 spotting, count (edge v. dead) 8 0 0 3 0 3 3 0 0
Day 10 1/27/2011 transfer, (edge v. dead*), start culture 5 0 3 1 0 2 3 0 0
Day 11 1/28/2011 spotting, count (edge v. dead) 5 0 0 0 0 1 1 0 2
Day 12 1/29/2011 transfer, (edge v. dead*), start culture 3 0 2 0 0 0 0 0 1
Day 13 1/30/2011 spotting, count (edge v. dead) 2 0 1 0 0 0
Day 14 1/31/2011 transfer, (edge v. dead*), start culture 1 0 1
Day 15 2/1/2011 spotting, count (edge v. dead) 1 0 0
Day 16 2/2/2011 transfer, (edge v. dead*), start culture 0 0 1
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Strain: fer-1 on ORF 19.1219
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 1/14/2011 start cultures (E.coli)
Day -2 1/15/2011 egg prep + spotting, start cultures
Day -1 1/16/2011 spotting
Day 0 1/17/2011 transfer same # of worms, start culture 5 0 0 5 0 0 5 0 0
Day 1 1/18/2011 spotting, count (edge v. dead) 5 0 0 5 0 0 4 0 1
Day 2 1/19/2011 transfer, (edge v. dead*), start culture 4 0 1 5 0 0 4 0 0
Day 3 1/20/2011 spotting, count (edge v. dead) 4 0 0 4 0 1 4 0 0
Day 4 1/21/2011 transfer, (edge v. dead*), start culture 4 0 0 4 0 0 3 1 0
Day 5 1/22/2011 spotting, count (edge v. dead) 4 0 0 4 0 0 3 0 0
Day 6 1/23/2011 transfer, (edge v. dead*), start culture 4 0 0 3 0 1 2 0 1
Day 7 1/24/2011 spotting, count (edge v. dead) 3 0 1 2 0 1 2 0 0
Day 8 1/25/2011 transfer, (edge v. dead*), start culture 1 0 2 1 0 1 1 0 1
Day 9 1/26/2011 spotting, count (edge v. dead) 0 0 1 1 0 0 1 0 0
Day 10 1/27/2011 transfer, (edge v. dead*), start culture 0 0 0 1 0 0 0 0 1
Day 11 1/28/2011 spotting, count (edge v. dead) 0 0 1 0 0 0
Day 12 1/29/2011 transfer, (edge v. dead*), start culture 0 0 0
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Strain: 2.5 mg/mL
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 start cultures (E.coli)
Day -2 egg prep + spotting, start cultures
Day -1 spotting
Day 0 12/2/2011 transfer same # (20) of worms, 20 0 0 20 0 0 20 0 0
Day 1 12/3/2011 count (edge v. dead) 20 0 0 19 0 1 20 0 0
Day 2 12/4/2011 count (edge v. dead), start cultures 19 0 1 18 0 1 20 0 0
Day 3 12/5/2011 count (edge v. dead), spot 19 0 0 18 0 0 20 0 0
Day 4 12/6/2011 transfer (edge v. dead*) 19 0 0 18 0 0 20 0 0
Day 5 12/7/2011 count (edge v. dead) 19 0 0 15 0 3 17 0 3
Day 6 12/8/2011 count (edge v. dead) start cultures 14 0 5 15 0 0 15 0 2
Day 7 12/9/2011 count (edge v. dead), spot 14 0 0 15 0 0 12 0 3
Day 8 12/10/2011 transfer (edge v. dead) 12 0 2 11 0 4 11 0 1
Day 9 12/11/2011 count (edge v. dead), start cultures 10 0 2 10 0 1 10 0 1
Day 10 12/12/2011 count (edge v. dead), spot 6 0 4 5 0 5 8 0 2
Day 11 12/13/2011 transfer (edge v. dead) 6 0 0 4 0 1 7 0 1
Day 12 12/14/2011 count (edge v. dead), start cultures 1 0 5 2 0 2 2 0 5
Day 13 12/15/2011 count (edge v. dead), spot 1 0 0 2 0 0 1 0 1
Day 14 12/16/2011 transfer (edge v. dead) 0 0 1 2 0 0 0 0 1
Day 15 12/17/2011 count (edge v. dead) 0 0 0 1 0 1 0 0 0
Day 16 12/18/2011 count (edge v. dead) start cultures 0 0 0 0 0 1 0 0 0
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Strain: 5 mg/mL
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 start cultures (E.coli)
Day -2 egg prep + spotting, start cultures
Day -1 spotting
Day 0 12/2/2011 transfer same # (20) of worms, 20 0 0 20 0 0 20 0 0
Day 1 12/3/2011 count (edge v. dead) 19 0 1 19 0 1 20 0 0
Day 2 12/4/2011 count (edge v. dead), start cultures 18 0 1 18 0 1 19 0 1
Day 3 12/5/2011 count (edge v. dead), spot 18 0 0 18 0 0 19 0 0
Day 4 12/6/2011 transfer (edge v. dead*) 18 0 0 18 0 0 19 0 0
Day 5 12/7/2011 count (edge v. dead) 16 0 2 16 0 2 16 0 3
Day 6 12/8/2011 count (edge v. dead) start cultures 16 0 0 15 0 1 16 0 0
Day 7 12/9/2011 count (edge v. dead), spot 15 0 1 12 1 2 16 0 0
Day 8 12/10/2011 transfer (edge v. dead) 13 0 2 12 0 0 16 0 0
Day 9 12/11/2011 count (edge v. dead), start cultures 13 0 0 10 0 2 12 0 4
Day 10 12/12/2011 count (edge v. dead), spot 5 0 8 8 0 2 12 0 0
Day 11 12/13/2011 transfer (edge v. dead) 5 0 0 5 0 3 7 0 5
Day 12 12/14/2011 count (edge v. dead), start cultures 0 0 5 2 0 3 4 0 3
Day 13 12/15/2011 count (edge v. dead), spot 0 0 0 2 0 0 1 0 3
Day 14 12/16/2011 transfer (edge v. dead) 0 0 0 1 0 1 1 0 0
Day 15 12/17/2011 count (edge v. dead) 0 0 0 0 0 1 0 0 1
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Strain: 10 mg/mL
Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 start cultures (E.coli)
Day -2 egg prep + spotting, start cultures
Day -1 spotting
Day 0 12/2/2011 transfer same # (20) of worms, 20 0 0 20 0 0 20 0 0
Day 1 12/3/2011 count (edge v. dead) 19 0 1 19 0 1 19 0 1
Day 2 12/4/2011 count (edge v. dead), start cultures 18 1 0 18 0 1 18 0 1
Day 3 12/5/2011 count (edge v. dead), spot 18 0 0 18 0 0 18 0 0
Day 4 12/6/2011 transfer (edge v. dead*) 18 0 0 18 0 0 18 0 0
Day 5 12/7/2011 count (edge v. dead) 18 0 0 16 0 2 17 0 1
Day 6 12/8/2011 count (edge v. dead) start cultures 18 0 0 16 0 0 16 0 1
Day 7 12/9/2011 count (edge v. dead), spot 18 0 0 14 0 2 16 0 0
Day 8 12/10/2011 transfer (edge v. dead) 11 0 7 11 0 3 16 0 0
Day 9 12/11/2011 count (edge v. dead), start cultures 7 0 4 11 0 0 15 0 1
Day 10 12/12/2011 count (edge v. dead), spot 3 0 4 5 0 6 10 0 5
Day 11 12/13/2011 transfer (edge v. dead) 3 0 0 3 0 2 5 0 5
Day 12 12/14/2011 count (edge v. dead), start cultures 0 0 3 2 0 1 3 0 2
Day 13 12/15/2011 count (edge v. dead), spot 0 0 0 1 0 1 1 0 2
Day 14 12/16/2011 transfer (edge v. dead) 0 0 0 0 0 1 1 0 0
Day 15 12/17/2011 count (edge v. dead) 0 0 0 0 0 0 0 0 1
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Strain: Control (0μM fluconazole)
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 3/15/2012 start cultures (E.coli)
Day -2 3/16/2012 egg prep + spotting, start cultures
Day -1 3/17/2012 spotting
Day 0 3/18/2012 transfer same # of worms, start culture 20 0 0 20 0 0 20 0 0
Day 1 3/19/2012 spotting, count (edge v. dead) 16 4 0 19 1 0 19 1 0
Day 2 3/20/2012 transfer, (edge v. dead*), start culture 15 0 1 19 0 0 13 3 3
Day 3 3/21/2012 spotting, count (edge v. dead) 13 0 2 17 1 1 11 0 2
Day 4 3/22/2012 transfer, (edge v. dead*), start culture 9 0 4 15 0 2 7 1 3
Day 5 3/23/2012 spotting, count (edge v. dead) 6 0 3 11 2 2 5 0 2
Day 6 3/24/2012 transfer, (edge v. dead*), start culture 2 0 4 10 0 1 5 0 0
Day 7 3/25/2012 spotting, count (edge v. dead) 2 0 0 8 0 2 2 0 3
Day 8 3/26/2012 transfer, (edge v. dead*), start culture 1 0 0 5 0 3 2 0 0
Day 9 3/27/2012 spotting, count (edge v. dead) 1 0 0 4 0 1 1 0 1
Day 10 3/28/2012 transfer, (edge v. dead*), start culture 0 0 1 3 0 1 1 0 0
Day 11 3/29/2012 spotting, count (edge v. dead) 1 0 2 1 0 0
Day 12 3/30/2012 transfer, (edge v. dead*), start culture 0 0 1 0 0 1
Plate B Plate CPlate A
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Strain: 50μM fluconazole
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 3/15/2012 start cultures (E.coli)
Day -2 3/16/2012 egg prep + spotting, start cultures
Day -1 3/17/2012 spotting
Day 0 3/18/2012 transfer same # of worms, start culture 20 0 0 20 0 0 20 0 0
Day 1 3/19/2012 spotting, count (edge v. dead) 18 2 0 18 2 0 18 2 0
Day 2 3/20/2012 transfer, (edge v. dead*), start culture 16 1 1 18 0 0 17 1 0
Day 3 3/21/2012 spotting, count (edge v. dead) 13 3 0 13 3 2 17 0 0
Day 4 3/22/2012 transfer, (edge v. dead*), start culture 13 0 0 12 0 1 17 0 0
Day 5 3/23/2012 spotting, count (edge v. dead) 13 0 0 10 0 2 17 0 0
Day 6 3/24/2012 transfer, (edge v. dead*), start culture 10 0 3 9 0 1 16 0 1
Day 7 3/25/2012 spotting, count (edge v. dead) 8 0 2 8 0 1 12 0 4
Day 8 3/26/2012 transfer, (edge v. dead*), start culture 7 0 1 7 0 1 12 0 0
Day 9 3/27/2012 spotting, count (edge v. dead) 7 0 0 5 0 2 10 0 2
Day 10 3/28/2012 transfer, (edge v. dead*), start culture 4 0 3 0 0 5 8 0 2
Day 11 3/29/2012 spotting, count (edge v. dead) 2 0 2 2 0 6
Day 12 3/30/2012 transfer, (edge v. dead*), start culture 1 0 1 0 0 2
Day 13 3/31/2012 spotting, count (edge v. dead) 0 0 1
Plate A Plate B Plate C
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Strain: 100μM fluconazole
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 3/15/2012 start cultures (E.coli)
Day -2 3/16/2012 egg prep + spotting, start cultures
Day -1 3/17/2012 spotting
Day 0 3/18/2012 transfer same # of worms, start culture 20 0 0 20 0 0 20 0 0
Day 1 3/19/2012 spotting, count (edge v. dead) 16 4 0 18 2 0 19 1 0
Day 2 3/20/2012 transfer, (edge v. dead*), start culture 16 0 0 15 0 3 16 2 1
Day 3 3/21/2012 spotting, count (edge v. dead) 15 1 0 14 1 0 16 0 0
Day 4 3/22/2012 transfer, (edge v. dead*), start culture 15 0 0 9 0 5 14 0 2
Day 5 3/23/2012 spotting, count (edge v. dead) 15 0 0 9 0 0 14 0 0
Day 6 3/24/2012 transfer, (edge v. dead*), start culture 15 0 0 8 0 1 10 0 4
Day 7 3/25/2012 spotting, count (edge v. dead) 14 0 1 4 0 4 8 0 2
Day 8 3/26/2012 transfer, (edge v. dead*), start culture 12 0 2 3 0 1 6 0 2
Day 9 3/27/2012 spotting, count (edge v. dead) 7 0 5 2 0 1 3 0 3
Day 10 3/28/2012 transfer, (edge v. dead*), start culture 3 0 4 1 0 1 1 0 2
Day 11 3/29/2012 spotting, count (edge v. dead) 2 0 1 1 0 0 0 0 1
Day 12 3/30/2012 transfer, (edge v. dead*), start culture 0 0 2 0 0 1
Plate A Plate B Plate C
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Strain: 150μM fluconazole
Day Date Task Alive Edge Dead Alive Edge Dead Alive Edge Dead
Day -3 3/15/2012 start cultures (E.coli)
Day -2 3/16/2012 egg prep + spotting, start cultures
Day -1 3/17/2012 spotting
Day 0 3/18/2012 transfer same # of worms, start culture 20 0 0 20 0 0 20 0 0
Day 1 3/19/2012 spotting, count (edge v. dead) 18 2 0 18 2 0 16 4 0
Day 2 3/20/2012 transfer, (edge v. dead*), start culture 18 0 0 18 0 0 16 0 0
Day 3 3/21/2012 spotting, count (edge v. dead) 18 0 0 18 0 0 16 0 0
Day 4 3/22/2012 transfer, (edge v. dead*), start culture 18 0 0 13 0 5 13 0 3
Day 5 3/23/2012 spotting, count (edge v. dead) 17 1 0 10 0 3 13 0 0
Day 6 3/24/2012 transfer, (edge v. dead*), start culture 15 2 0 6 0 4 11 0 2
Day 7 3/25/2012 spotting, count (edge v. dead) 15 0 0 6 0 0 6 0 5
Day 8 3/26/2012 transfer, (edge v. dead*), start culture 13 0 2 5 0 1 4 0 2
Day 9 3/27/2012 spotting, count (edge v. dead) 10 0 3 5 0 0 3 0 1
Day 10 3/28/2012 transfer, (edge v. dead*), start culture 4 0 6 2 0 3 1 0 2
Day 11 3/29/2012 spotting, count (edge v. dead) 2 0 2 0 0 2 0 0 1
Day 12 3/30/2012 transfer, (edge v. dead*), start culture 1 0 0
Day 13 3/31/2012 spotting, count (edge v. dead) 0 0 1
Plate A Plate B Plate C
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